Effects of the N-type Ca2+ channel blocker, Cilnidipine: Atelec&reg;, on blood pressure levels and atherosclerosis indices in hypertensive patients with cerebrovascular disease.

Effects of the N-type Ca2+ channel blocker, Cilnidipine: Atelec&reg;, on blood pressure levels and atherosclerosis indices in hypertensive patients with cerebrovascular disease. - Carotid Atherosclerosis- Antihypertensive Treatment Trial, Effect of N-type CCB for cerebrovascular Disease (CA-ATTEND).

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000005523

Enrollment

3000

Registered

2011-04-28

Start date

2011-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential Hypertension

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Atelec-naive patients with essential hypertension and cerebrovascular disease.

Exclusion criteria

Exclusion criteria: Pregnant or possibly pregnant patients.

Design outcomes

Primary

Measure	Time frame
Change in blood pressure levels	—

Secondary

Measure	Time frame
Adverse events, changes of atherosclerosis indices.	—

Countries

Japan

Contacts

Public ContactEiichi Ohara

Mochida Pharmaceutical Co., Ltd. Post-Marketing Surveillance

atelec.ms.tokutei@mochida.co.jp03-3225-6342

Outcome results